HCPCS code J0330 – Succinylcholine chloride injection

Key takeaways

HCPCS code J0330 bills succinylcholine chloride injection at one unit per 20 mg administered, and any partial 20 mg increment counts as a full unit.

NDC reporting is mandatory for Medicaid and required by most commercial payers, with qualifier LN and an ML unit of measure for liquid vials.

JW and JZ apply to Medicare Part B claims for single-dose containers. Confirm J0330’s status on the CMS JW/JZ list, and note that other payers set their own rules.

Pabau’s claims management software submits CMS-1500 claims through Claim.MD in the US.

HCPCS code J0330: Definition and clinical overview

HCPCS code J0330 is the Level II code the Centers for Medicare and Medicaid Services (CMS) maintains for injection, succinylcholine chloride, up to 20 mg. It sits in the J0000-J9999 range (J codes, drugs administered other than oral method). Each billing unit covers up to 20 mg of drug given to the patient, not the amount dispensed or drawn.

Drug description: Succinylcholine chloride

Succinylcholine chloride is a depolarizing neuromuscular blocking agent (NMBA). It binds to nicotinic acetylcholine receptors at the neuromuscular junction, causing brief muscle fasciculations followed by paralysis.

The label puts onset within about 1 minute of an IV dose. Paralysis typically lasts about 4 to 6 minutes, and up to about 10 minutes, which makes it a common choice for rapid sequence intubation (RSI).

The FDA-approved indications are as an adjunct to general anesthesia, to facilitate tracheal intubation, and to relax skeletal muscle during surgery or mechanical ventilation. Laryngospasm management and muscle relaxation during electroconvulsive therapy (ECT) are off-label but common uses.

Common vial concentrations are 20 mg/mL (200 mg/10 mL) and 50 mg/mL, though higher concentrations are available. Most formulations need refrigeration. Record storage conditions and the lot number in the medical record to support wastage documentation.

What J0330 covers and what it does not

J0330 covers physician-administered succinylcholine chloride injection in the non-facility physician office setting, billed in 20 mg increments given to the patient. The scope is narrow. It covers only the drug charge, and only for succinylcholine chloride. It also applies only when the physician practice bills the drug separately, outside a bundled facility payment.

• Covered: IV and IM administration of succinylcholine chloride in 20 mg increments, including doses for RSI, surgical muscle relaxation, and ECT
• Not covered under J0330: Compounded succinylcholine formulations that are not FDA-approved, which are billed under a Not Otherwise Classified (NOC) code with an invoice
• Not covered under J0330: The administration service itself (billed separately under CPT 96374 or 96372)
• Not covered under J0330: Succinylcholine given in an outpatient hospital setting where the drug is bundled into the facility APC payment
• Not covered under J0330: Other neuromuscular blocking agents such as vecuronium, rocuronium and cisatracurium. Check the current HCPCS file for their own code, or use the NOC code J3490 where none exists

How to calculate billing units for J0330

Each billing unit of J0330 covers up to 20 mg of succinylcholine chloride. Divide the dose in milligrams by 20, then round up to the next whole unit. Any partial 20 mg increment counts as another unit, so a 30 mg dose is 2 units.

The main claim line bills the dose given to the patient, not the whole vial. When part of a single-dose vial is discarded and the JW modifier applies, the discarded amount goes on its own JW line.

The medical record must show the dose given in milligrams, not just the vial size drawn. A chart note stating “succinylcholine administered per protocol” without a milligram dose does not support the billed units and will fail audit. For how the drug line and the administration line fit into one claim, start with medical billing fundamentals.

NDC reporting requirements for J0330

The National Drug Code (NDC) is an FDA-assigned identifier for every drug product, reported on claims in an 11-digit form. Reporting the NDC alongside J0330 is mandatory for Medicaid and required by most commercial payers.

Medicare Part B does not mandate it for physician-administered drugs at the federal level. Many Medicare Advantage plans and supplemental payers do, so including it on every claim line is best practice.

• NDC format: Report the NDC in the 11-digit 5-4-2 labeler-product-package format. Vial labels print 10-digit NDCs as 4-4-2, 5-3-2 or 5-4-1. Add a leading zero to the labeler (4-4-2), product (5-3-2) or package (5-4-1) segment to reach 5-4-2.
• Qualifier on the claim: Use qualifier LN to show the value is an NDC. It goes in 837P Loop 2410, or the supplemental field of CMS-1500 Box 24A.
• Unit of measure qualifier: Report succinylcholine solution as ML (milliliters) for liquid vials. UN applies only to items packaged as units. Enter the milliliters that match the administered dose.
• Which NDC to use: Use the NDC printed on the vial you administered from. If several vials of the same drug are used across encounters on the same date, each claim line reflects the vial drawn for that encounter.

Modifier requirements when billing J0330

JW and JZ are Medicare Part B (fee-for-service) modifiers for drugs supplied in single-dose containers. JW reports an amount discarded, and it was already required for any discarded amount before 2023. JZ is the newer modifier that attests no drug was wasted. JW/JZ refund reporting began January 1, 2023, and CMS required JZ no later than July 1, 2023.

Neither modifier applies to multi-dose vials. One third-party billing reference notes that J0330 is not on the CMS list of single-dose-container drugs. Confirm its status on the current CMS JW/JZ list before adding either. Other payers set their own rules. The three questions below settle which line, if any, a J0330 claim takes.

Where JW/JZ applies, CMS expects JZ on every single-dose-container line with zero waste from July 1, 2023. A line that carries neither modifier can be returned or denied. If J0330 appears on the current CMS list, audit Medicare Part B claims since that date that lack both modifiers and resubmit them correctly.

Medicare and Medicaid coverage for J0330

Medicare Part B covers physician-administered injectable drugs, including succinylcholine under J0330, when given incident to a physician’s service in a non-facility setting. Reimbursement follows the Average Sales Price (ASP) plus 6% method. CMS publishes the payment limits each quarter in the CMS ASP drug pricing files.

Place of service and facility billing considerations

Where succinylcholine is given decides whether J0330 can be billed separately or is bundled into the facility’s payment. Getting this wrong is a frequent billing error for anesthesia-related drug codes.

Pairing J0330 with drug administration CPT codes

J0330 covers the drug charge only. When the physician practice bills both the drug and the injection service, a separate CPT administration code goes on the same claim. That is most often CPT 96374 for an IV push. These are two distinct line items, billed together.

96374 and 96375 are not reported when the drug is given as part of an anesthesia service. In facility settings (outpatient hospital, ASC), the facility typically bills the administration code. The physician practice bills the professional service, such as the anesthesia CPT code, but generally not the drug administration code.

Codes commonly confused with J0330

Two kinds of confusion show up in J0330 coding audits. One is a single-digit mix-up with J9330. The other is clinical, where a different neuromuscular blocker is coded as succinylcholine.

Rocuronium is often used in place of succinylcholine for RSI, and vecuronium and cisatracurium appear on the same anesthesia records. None of them bills under J0330.

Check the drug name and unit dose for any HCPCS drug in the AAPC Codify HCPCS lookup or the annual CMS HCPCS file. Don’t rely on memory or auto-populated EHR fields without confirming the code still matches the current year’s descriptor.

Documentation requirements to support J0330 claims

Every billed unit of J0330 must trace to a medical record entry. Medicare, Medicaid and commercial auditors look for each of these elements when reviewing J0330 claims. Missing even one creates a recoupment exposure.

• Physician order: A dated, signed order specifying succinylcholine chloride and the intended dose or dose range
• Drug name and concentration: The specific product given (for example, Anectine 20 mg/mL), enough to identify the NDC
• Dose administered in milligrams: The number of milligrams given to the patient, not the volume drawn or the vial size
• Route of administration: IV push or IM injection, matching the CPT administration code billed
• Date and time: The date of administration, with time required in emergency and anesthesia contexts
• Administering provider: Name and credentials of the person who gave the injection
• Vial lot number and NDC: Needed for wastage tracking and NDC reporting, recorded from the physical vial label
• Wastage amount (if any): The milligrams drawn but not given, supporting a JW line where that modifier applies

Mapping each of these elements to a claim field is the core of clean claim submission. A superbill can capture drug name, dose, lot number and route at the point of care. Billing staff then complete the J0330 line without returning to the clinical record.

Prior authorization requirements for J0330

Medicare Part B does not require prior authorization for succinylcholine in most clinical settings. Succinylcholine is used mainly in emergency and urgent contexts (RSI, laryngospasm, ECT), so payers generally accept that advance approval isn’t clinically feasible.

Commercial managed care plans and Medicaid managed care organizations may require prior authorization (PA) for scheduled, non-emergency uses. Practices using succinylcholine for elective procedures such as ECT should check PA requirements plan by plan before the date of service. A typical PA request includes these details:

• The ICD-10 diagnosis code
• The procedure being performed
• The clinical rationale for a depolarizing rather than a non-depolarizing NMBA
• The anticipated dose

Keeping medical billing compliance documentation for each encounter supports both the PA submission and any later audit defense.

Common reasons J0330 claims are denied

Most J0330 denials fall into five categories. Each carries a claim adjustment reason code (CARC) on the remittance advice, and the guide to medical billing denial codes explains the wider set. Spotting the pattern on the first denial stops the same error repeating on later claims.

For Medicare denials, file the redetermination request within 120 days of receiving the initial determination. Receipt is presumed 5 days after the notice date. Gather the physician order, administration record, NDC vial label, and any documentation supporting the modifier used.

Submit through the contractor’s portal with a cover letter citing the specific denial reason and the documentation that refutes it. Denial management workflows that log each denial by reason code show patterns across the whole billing cycle, beyond the single claim in front of you.

How Pabau’s claims software supports J0330 billing

Most J0330 errors start in the handoff from the anesthesia record to the claim. Someone has to turn a milligram dose into units, copy the NDC and quantity, and decide whether a waste modifier applies.

Pabau, the practice management platform we build, handles the claim side of that handoff. Its claims management software submits CMS-1500 claims through Claim.MD in the US and checks insurance eligibility before the visit. Claim validation scrubs each claim for missing or invalid details before it leaves Pabau.

If a claim still comes back rejected, Pabau flags it as Needs action and links straight to the field to correct. Prior authorizations are stored as cases that follow the appointment through to the claim, which helps when a plan requires PA for scheduled ECT.

Submit cleaner J-code claims with fewer denials

Pabau submits CMS-1500 claims through Claim.MD and scrubs each one for missing or invalid details first. Your billing team fixes flagged J0330 claims before they turn into resubmissions.

Book a demo

Conclusion

J0330 rewards precision at the bedside more than effort in the billing office. Chart the dose in milligrams, round partial 20 mg increments up, and report the NDC in milliliters. Do that and most J0330 denials never reach your remittance advice.

Settle the JW/JZ question once a year by checking J0330 on the current CMS list, then apply each commercial payer’s own rule. Medicare Part B single-dose rules don’t carry over to multi-dose vials or other payers.

The trade-off is a few seconds of charting now against a resubmission weeks later. Book a demo to see how Pabau submits CMS-1500 claims and checks eligibility for your drug administration billing.

Continue your research

Need a framework for cleaner drug billing claims? Medical billing fundamentals walks through the end-to-end process of turning a drug administration encounter into a paid claim.

Struggling with repeated J-code rejections? Denial management in healthcare covers systematic approaches to tracking, appealing, and preventing recurring claim denials.

Want to reduce first-pass claim errors? Clean claim submission outlines the documentation and coding checks that prevent common billing errors before the claim leaves your practice.

Billing the IV push that delivered the dose? CPT code 96374 covers the administration code that most often pairs with J0330.

Filling in the claim form by hand? CMS-1500 form template shows where the J-code, units and NDC supplemental data go on a paper claim.

Frequently asked questions